BlackRock Advisors’s Anika Therapeutics ANIK Stock Holding History

BlackRock Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$406K	Buy	8,291 +386	+5%	+$17.8K	﹤0.01%	2319
2016 Q3	$378K	Sell	7,905 -15,787	-67%	-$780K	﹤0.01%	2319
2016 Q2	$1.27M	Buy	23,692 +355	+2%	+$16.7K	﹤0.01%	1659
2016 Q1	$1.04M	Sell	23,337 -2,198	-9%	-$89.2K	﹤0.01%	1720
2015 Q4	$974K	Sell	25,535 -18,290	-42%	-$700K	﹤0.01%	1723
2015 Q3	$1.4M	Sell	43,825 -124,356	-74%	-$4.34M	﹤0.01%	1508
2015 Q2	$5.55M	Sell	168,181 -4,485	-3%	-$160K	0.01%	962
2015 Q1	$7.11M	Buy	172,666 +1,385	+0.8%	+$56K	0.01%	887
2014 Q4	$6.98M	Buy	171,281 +1,840	+1%	+$71.9K	0.01%	877
2014 Q3	$6.21M	Buy	169,441 +69,993	+70%	+$3.02M	0.01%	920
2014 Q2	$4.61M	Buy	99,448 +87,025	+701%	+$3.87M	﹤0.01%	994
2014 Q1	$511K	Sell	12,423 -6,222	-33%	-$231K	﹤0.01%	2030
2013 Q4	$711K	Sell	18,645 -100,800	-84%	-$3.11M	﹤0.01%	1751
2013 Q3	$2.85M	Buy	119,445 +111,888	+1,481%	+$2.51M	﹤0.01%	1091
2013 Q2	$128K	Buy	+7,557	New	+$109K	﹤0.01%	2736

Other funds holding ANIK

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's ANIK Position: Q4 2016 in Review

BlackRock Advisors increased its Anika Therapeutics (ANIK) stake by 4.9% in Q4 2016, buying an estimated $17.8K and bringing the position to 8,291 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

BlackRock Advisors first reported a position in ANIK in Q2 2013 and has held it in 15 quarters since. The position peaked at $7.11M in Q1 2015. 158 funds tracked by Wall St. Rank hold ANIK as of Q4 2016.

BlackRock Advisors held 8,291 shares of Anika Therapeutics worth $406K as of Q4 2016.
BlackRock Advisors bought 386 Anika Therapeutics shares in Q4 2016, an estimated $17.8K.
Anika Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2319 holding.
BlackRock Advisors first reported a position in Anika Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Anika Therapeutics position peaked at $7.11M in Q1 2015.
158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.